Lupin gets USFDA nod to generic version of ProAir HFA

Lupin's generic Albuterol Sulphate MDI will be manufactured at its Indore (Unit III) facility in India.;

Published On 2020-08-25 07:15 GMT | Update On 2020-08-25 08:25 GMT

Mumbai: Pharma major Lupin Limited announced today that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Albuterol Sulfate Inhalation Aerosol, 90 mcg (base)/actuation, a generic version of ProAir® HFA.

Lupin's generic Albuterol Sulphate MDI will be manufactured at its Indore (Unit III) facility in India.

ProAir® HFA (Albuterol Sulfate Inhalation Aerosol) is the registered trademark of Teva Branded Pharmaceutical Products R&D, Inc. (Teva) and is indicated for the treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms.

Commenting on the development, Vinita Gupta, CEO, Lupin said, "Approval of our generic Albuterol MDI is a significant milestone in our complex generics evolution and a validation of our Inhalation team's development capabilities, backed by our global manufacturing strength in handling multiple dosage forms. The approval is timely as Albuterol MDI is a key rescue inhalation product for asthma patients who are at an increased risk of COVID-related complications. We look forward to launching the product this quarter and expect a steady rampup through the fiscal year."

The total Albuterol Sulfate Inhalation Aerosol market had U.S. sales of approximately US$2.9 billion, of which the ProAir® HFA market accounted for US$1.3 billion (IQVIA MAT June 2020).

Lupin Limited is a global pharmaceutical company based in Mumbai, Maharashtra, India.

The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Lupin gets USFDA nod to generic version of ProAir HFA

Lupin's generic Albuterol Sulphate MDI will be manufactured at its Indore (Unit III) facility in India.;

Similar News

Keeping Medicines Without Licence Amounts to 'Offer for Sale', HC Upholds Chemist's Conviction

Lupin Manufacturing Solutions: Empagliflozin API gets CADIFA approval from ANVISA, Brazil

Zydus Foundation Vice Chairperson Meha Patel appointed as Member of CII National Committee on Art & Culture for 2025-26

Eris Lifesciences Secures CDSCO Panel Nod to Conduct BE Study on Dapagliflozin, Pioglitazone, Metformin FDC

Delhi to form special committee to crush fake medicine racket

Roche Pharma teams up with 10 Govt Hospitals to power up clinical trial capacities in India

AstraZeneca's Proposal to Increase Sample Size in Zibotentan-Dapagliflozin Global Trial Gets SEC Nod

Govt Allows Stickering, Orders New MRPs Post GST Reduction, AiMeD Welcomes Directive